Region — US. Neutral scientific reference — not offered for sale here.
Set region
Vallydia
ExploreShopToolsJournalTrustSearch ⌕
Explore  /  GHRP-6
Research reference — not for sale

GHRP-6

B
best evidence
Peptide⚠ WADA-banned
also called — GHRP-6 · Growth Hormone Releasing Peptide-6 · sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. INCI: none
GH secretagogue / ghrelin agonistappetite stimulation(research context)

Reference entry — not sold here. Historically the most important peptide in this class: the first GHRP, and the compound whose study led to the discovery of ghrelin. Not approved anywhere; the marketed anti-aging use is untested in humans. No dosing published here. GH-secretagogue class — now fully

In brief

GHRP-6 is the original growth-hormone-releasing peptide (Bowers, 1984) — the compound from which the entire GH-secretagogue class descends, and whose study led to the discovery of the ghrelin receptor (1996) and ghrelin itself (1999). It reliably raises GH but is non-selective, producing the strongest appetite stimulation of any GHRP plus modest cortisol/prolactin. It is not approved anywhere, and the popular anti-aging / muscle use is untested in humans. Banned in sport.

Legal standing, by region
International
See note

- Everywhere — not approved for human therapeutic use; a research compound (503A Category-2 / gray-market). (Unlike GHRP-2, GHRP-6 has no approval anywhere.) - ⚠ Sport: WADA-prohibited at all times — Section S2.2 (GH secretagogues).

⚠ WADA-prohibited in sportSport: WADA-prohibited at all times — Section S2.2 (GH secretagogues).
Evidence, by outcome

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
GH release
Real, foundational pharmacology
Extensive characterisation (Bowers 1984 onward) + human PK · Strong, dose-dependent GH pulse
B
Appetite stimulation (cachexia / wasting research)
A feature for cachexia, a drawback for GH/fat-loss goals; preclinical as a therapy
Preclinical + Phase 1 observations · Strongest of any GHRP
C
Anti-aging / body composition / muscle (the popular use)
Untested for these goals
None in humans · Not demonstrated
F
Safety
Strong hunger; raises cortisol (~15–20% transient) and prolactin; long-term unknown; WADA-banned
Research + PK data · Characterised (short-term)

Identity a synthetic hexapeptide (6 amino acids, with two D-residues for protease resistance; < 40 aa → peptide), a ghrelin-receptor (GHS-R1a) agonist. Half-life ~2.5 h. ## Development & history - GHRP-6 was the first growth-hormone-releasing peptide, synthesised and characterised by Cyril Y. Bowers at Tulane University in 1984 (Bowers, Momany, Reynolds, Hong). It emerged from systematic modification of met-enkephalin analogs — Bowers noticed some enkephalin derivatives had unexpected GH-releasing activity unrelated to opioid receptors. Every later GH secretagogue (GHRP-2, hexarelin, ipamorelin, the oral MK-677) descends from it.

  • The "fake key": GHRP-6 activated a receptor no one had identified. Characterising it led first to the cloning of the GH-secretagogue receptor (GHS-R1a) in 1996 (Howard et al.), and then — hunting for that receptor's natural ligand — to the discovery of ghrelin in 1999 (Kojima & Kangawa, Osaka), found surprisingly in the stomach. GHRP-6 thus opened up the entire ghrelin / gut-brain hunger-and-GH axis. Its strong appetite effect, first dismissed as a side effect, turned out to be the crucial clue (ghrelin signals both hunger and GH). ## Mechanism (as proposed) GHRP-6 binds GHS-R1a on two populations — pituitary somatotrophs (driving GH release via the Gq-PLC-calcium pathway) and hypothalamic arcuate-nucleus orexigenic neurons (driving hunger). The same receptor drives both GH and appetite, exactly as endogenous ghrelin does physiologically. Its non-selectivity comes from additional HPA-axis (cortisol) and prolactin activation, plus gastric-motility effects.
Sources — 3 cited
01Bowers CY, Momany FA, Reynolds GA, Hong A. (Characterisation of GHRP-6 — the first GHRP.) 1984.
02Howard AD, et al. (Cloning of the GH-secretagogue receptor, GHS-R.) Science, 1996.
03Kojima M, Kangawa K, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. (the endogenous ligand GHRP-6 pointed to)
Review status
Not yet reviewed

A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026.

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
GHRP-2 (Pralmorelin)B
Peptide
IpamorelinB
Peptide
Explore by goal
GH & endocrine
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterCategoriesTrust & COA
ShopCosmetic peptidesJournal
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

GHRP-6 — evidence, the ghrelin-discovery story & status · Vallydia